Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Contact:Joshua T. Brumm
Executive Vice President, Finance
Phone: 408-215-3311

Ramses Erdtmann
Vice President of Investor Relations
Phone: 408-215-3325Pharmacyclics, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands)

 December 31,June 30, 20122012AssetsCash, cash equivalents and marketable securities 1

$
317,114$
203,607Other current assets 2

29,3789,788Total current assets

346,492213,395Property and equipment, net

6,4033,842Other assets

2,2341,883Total assets

$
355,129$
219,120Liabilities and Stockholders' EquityDeferred revenue - current portion

$
8,139$
8,054Other current liabilities

21,11810,932Total current liabilities

29,25718,986Deferred revenue - non-current portion

62,56267,324Deferred rent

784687Total liabilities

92,60386,997Stockholders' equity

262,526132,123Total liabilities and stockholders' equity

$
355,129$
219,1201Marketable securities

$
9,681$
5,7112As of December 31, 2012 and June 30, 2012, Other current assets includes $26.6 million and $5.8 million, respectively, due to t
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Chromatography and Mass Spectrometry Application Note , ... Structure Elucidation Metabolite ID Mass Frontier , ... Introduction , ... plays a crucial role throughout its development. In the early discovery phase, ...
... and Mass Spectrometry Application Note , ... Thermo Electron Corporation, Somerset, NJ, USA , ... Acrylamide has been identified as a ... common industrial chemical, but acrylamide was recently discovered to be present at ...
... Gargi Choudhary, Tania A. Sasaki, and ... Chromatography and Mass Spectrometry ... Introduction , Ion trap mass ... MS n such as for structural elucidation and identification of ...
Cached Biology Technology:Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 2Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 3Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 4Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 5Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 6Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 7Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 8Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 9Analysis of a Verapamil Microsomal Incubation using Metabolite ID and Mass FrontierTM 10Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 2Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 3Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 4Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 5Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 6Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
(Date:10/15/2014)... book ,Models of Life, is a non-traditional biophysics textbook ... The book is a journey of discovery into biological ... life and biological regulation. It is about how our ... communication between the billions of cells in an organism. ... relationships between principles, which can be found on both ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... Vincetoxicum rossicum ) is an exotic plant originating ... increasingly invasive in southern Ontario, Canada. It has been ... in open fields, forest edges and understories, parks, road ... for light by forming large and dense stands that ...
... Crusafont Catalan Palaeontology Institute has for the first time documented ... Narg archaeological site in Lleida, Spain. Up until now, only ... region. , The archaeological site in Coll de Narg containing ... the town that bears the same name in the province ...
... Alex Pyron,s expertise is in family trees. Who is related ... they are now. But not for humans: reptiles. In ... the island led him to confirm the identity of 60 ... an author on snakes and expert on amphibians and reptiles, ...
Cached Biology News:A European invader outcompetes Canadian plants even outside its usual temperature range 24 dinosaur egg species identified in Lleida 2Sri Lankan snake study reveals new species, rich biodiversity in island country 2
P2A4...
pETDuet-1 is designed for the coexpression of two target genes....
... Cl- Cotransporter-1 (KCC1). The ... sequence homology with other ... The immunogen sequence is ... mouse, porcine and rabbit. ...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Biology Products: